Autoimmune Diseases

$100B+
Combined Research Spending
24M+
Americans Affected
80+
Diagnosed Autoimmune Conditions
0
Autoimmune Cures Approved

The Numbers

Autoimmune diseases are a broad category of conditions in which the immune system attacks the body's own cells and tissues. The category includes lupus, multiple sclerosis, rheumatoid arthritis, Crohn's disease, type 1 diabetes, and over 80 other recognized conditions. Over 24 million Americans are affected. Over $100 billion has been invested in research across these conditions.

No autoimmune disease has a cure. All have management protocols. The treatment paradigm remains unchanged for decades: suppress the immune system, manage symptoms, prevent progression. The fundamental scientific problem remains unsolved: why does the immune system attack itself.

Recognized Autoimmune Conditions 80+
Americans With Autoimmune Diagnosis 24M+
Autoimmune Disease Cures 0
Treatment Goal Symptom management

Promises vs. Reality

1940s
Reality: Cortisone discovered. First effective treatment for autoimmune inflammation. Significant side effects with long-term use.
1990s
Reality: TNF inhibitors developed. Monoclonal antibodies enter clinical use. Improved symptom management. No cures.
2010s
Promise: Targeted biologics expand. JAK inhibitors show results. Precision medicine approaches multiply. Cure research accelerates.
2020
Reality: Improved symptom management. Extended remission periods. Complete cures remain absent across all conditions.
2022--2024
Promise: CAR-T therapy shows early results in lupus trials. Small patient cohorts (less than 50). Significant safety concerns remain.
2024
Reality: CAR-T therapy remains experimental. Fundamentally, we still do not understand why the immune system attacks itself.

Current Research Status

Autoimmune disease research has diversified significantly. The treatment paradigm still centers on immune suppression -- killing or silencing the immune cells that attack the body. This approach manages symptoms but cannot address the root cause because we do not yet understand why the immune system initiates these attacks in the first place.

CAR-T therapy, an engineering approach borrowed from cancer research, represents a new direction. Early lupus trials show it can reduce disease activity. However, sample sizes remain small, long-term outcomes are unknown, and the approach raises new safety questions. This remains experimental, not approved, not a cure.

Active Clinical Trials (Autoimmune) 400+
CAR-T Trials for Autoimmunity 3--4
CAR-T Lupus Trial Patient Count Less than 50
Autoimmune Disease Cures Approved 0

Sources & Methodology

Data compiled from NIH, peer-reviewed immunology literature, FDA approval records, ClinicalTrials.gov, and epidemiological studies.

Primary Sources

  • U.S. National Institutes of Health -- Autoimmune Research Funding (RePORT Database)
  • NIH National Institute of Allergy and Infectious Diseases -- Autoimmune Disease Overview
  • ClinicalTrials.gov -- Autoimmune Disease Clinical Trials Registry (400+ active trials)
  • FDA Center for Drug Evaluation and Research -- Autoimmune Drug Approvals Timeline
  • Nature Immunology -- CAR-T Therapy for Autoimmune Disease Research (2022--2024)
  • The Lancet -- Autoimmune Disease Epidemiology and Treatment Paradigm Reviews
  • Arthritis & Rheumatology Journal -- TNF Inhibitor and Biologic Safety Data